Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection

AIDS

Volumn 14, Issue 10, 2000, Pages 1309-1316

  Mallal, Simon A ^a   John, Mina ^a   Moore, Corey B ^a,b   James, Ian R ^b   McKinnon, Elizabeth J ^b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b MURDOCH UNIVERSITY   (Australia)

Author keywords

Lipodystrophy; Mitochondrial cytopathy; Nucleoside analogue reverse transcriptase inhibitor; Protease inhibitor; Subcutaneous fat wasting

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; COHORT ANALYSIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INSULIN RESISTANCE; LIPID STORAGE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE; SUBCUTANEOUS FAT; WASTING SYNDROME;

ADIPOSE TISSUE; ADULT; COHORT STUDIES; DENSITOMETRY, X-RAY; DIDANOSINE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV WASTING SYNDROME; HUMANS; LAMIVUDINE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; STAVUDINE; TIME FACTORS; ZIDOVUDINE;

EID: 0033924871     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200007070-00002     Document Type: Article

References (24)

1. 1. Viraben R, Aquilina C. Indinavir associated lipodystrophy. AIDS 1998, 12:F37-F39.
2. 2. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
3. 3. Gervasoni C, Ridolfo AL, Trifiro G et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999, 13:465-472.
4. 4. Carr A, Samaras K, Chisholm DJ et al. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998, 351:1881-1883.
5. 5. Saint-Marc T, Poizot-Martin L, Partisani et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999, 13:1659-1667.
6. 6. Madge S, Kinloch-de-Loes, Mercey D et al. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 1999,13: 735-737.
7. 7. Mallal S. The Western Australian HIV Cohort Study, Perth, Australia. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17(Suppl. 1):S23-S27.
8. 8. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
9. 9. Stein DS. A new syndrome of hepatomegaly with severe steatosis in HIV seropositive patients. AIDS Clin Care 1994, 6:19-20.
10. 10. Fortgang IS, Belitsos PC, Chaisson RE et al. Hepatomegaly and steatosis in HIV infected patients receiving nucleoside analogue antiretroviral therapy. Am J Gastrol 1995, 90:1433-1436.
11. 11. Olano JP, Boruki MJ, Wen JW et al. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. Clin Infect Dis 1995, 21:973-976.
12. 12. Lenzo NP, Garas BA, French MA. Hepatic steatosis and lactic acidosis associated with stavudine treatment in a HIV patient: a case report. AIDS 1997, 11:1294-1296.
13. 13. Brinkman K, ter Hofstede HJM, Burger DM et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as a common pathway. AIDS 1998, 12:1735-1744.
14. 14. John M, Mallal S, French M. Emerging toxicity with long-term antiretroviral therapy. J HIV Ther 1998, 3:58-62.
15. 15. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995, 1:417-421.
16. 16. Fry M, Loeb LA. Animal Cell Polymerases 221. Boca Raton, FL: CRC Press; 1986.
17. 17. Wang H, Lemire BD, Cass CE et al. Zidovudine and dideoxynucleosides deplete wild-type mitochondrial DNA levels and increase deleted mitochondrial DNA levels in cultured Kearns-Sayre syndrome fibroblasts. Biochim Biophys Acta 1996, 1316:51-59.
18. 18. Schapira AH. Inborn and induced defects of mitochondria. Arch Neurol 1998, 55:1293-1296.
19. 19. Hirano N, Silvestri D, Blake DM. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE); clinical, biochemical and genetic features of an autosomal recessive mitochondrial disorder. Neurology 1994, 44:721-727.
20. 20. Cui L, Locatelli L, Xie MY et al. Effect of nucleoside analogues on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells. J Pharmacol Exp Ther1997, 280:1228-1234.
21. 21. Stevens GJ, Chen M, Greko R et al. Investigations into proposed mechanisms of HIV-associated peripheral lipodystrophy, hyperlipidemia and insulin resistance. First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, June 1999 [abstract 058].
22. 22. Lenhard JM, Weiel JE, Paulik MA et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January, 1999 [abstract 665].
23. 23. Lenhard JM, Kliewer SA, Paulik MA et al. Effects of troglitizone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways. Biochem Pharmacol 1997, 54:801-808.
24. 24. Mallal SA, James IR, French MAH. Detection of subclinical Mycobacterium avium intracellulare complex infection in immunodeficient HIV-infected patients treated with zidovudine. AIDS 1994, 8:1263-1269.